Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Globular glial tauopathy caused by MAPT P301T mutation: clinical and neuropathological findings.

Erro ME, Zelaya MV, Mendioroz M, Larumbe R, Ortega-Cubero S, Lanciego JL, Lladó A, Cabada T, Tuñón T, García-Bragado F, Luquin MR, Pastor P, Ferrer I.

J Neurol. 2019 Oct;266(10):2396-2405. doi: 10.1007/s00415-019-09414-w. Epub 2019 Jun 12.

PMID:
31190169
2.

Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson's Disease.

Martínez-Pinilla E, Aguinaga D, Navarro G, Rico AJ, Oyarzábal J, Sánchez-Arias JA, Lanciego JL, Franco R.

Mol Neurobiol. 2019 Aug;56(8):5900-5910. doi: 10.1007/s12035-019-1495-4. Epub 2019 Jan 28.

PMID:
30687889
3.

Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine.

Blandini F, Cilia R, Cerri S, Pezzoli G, Schapira AHV, Mullin S, Lanciego JL.

Mov Disord. 2019 Jan;34(1):9-21. doi: 10.1002/mds.27583. Epub 2018 Dec 27. Review.

PMID:
30589955
4.

History and future challenges of the subthalamic nucleus as surgical target: Review article.

Guridi J, Rodriguez-Rojas R, Carmona-Abellán M, Parras O, Becerra V, Lanciego JL.

Mov Disord. 2018 Oct;33(10):1540-1550. doi: 10.1002/mds.92. Epub 2018 Oct 4. Review.

PMID:
30288779
5.

Glucocerebrosidase Mutations and Synucleinopathies. Potential Role of Sterylglucosides and Relevance of Studying Both GBA1 and GBA2 Genes.

Franco R, Sánchez-Arias JA, Navarro G, Lanciego JL.

Front Neuroanat. 2018 Jun 28;12:52. doi: 10.3389/fnana.2018.00052. eCollection 2018.

6.

Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death.

Rodriguez-Perez AI, Sucunza D, Pedrosa MA, Garrido-Gil P, Kulisevsky J, Lanciego JL, Labandeira-Garcia JL.

Neurotherapeutics. 2018 Oct;15(4):1063-1081. doi: 10.1007/s13311-018-0646-z.

7.

Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.

Castro-Sánchez S, García-Yagüe ÁJ, López-Royo T, Casarejos M, Lanciego JL, Lastres-Becker I.

Glia. 2018 Aug;66(8):1752-1762. doi: 10.1002/glia.23338. Epub 2018 Apr 6.

PMID:
29624735
8.

Alterations in Gene and Protein Expression of Cannabinoid CB2 and GPR55 Receptors in the Dorsolateral Prefrontal Cortex of Suicide Victims.

García-Gutiérrez MS, Navarrete F, Navarro G, Reyes-Resina I, Franco R, Lanciego JL, Giner S, Manzanares J.

Neurotherapeutics. 2018 Jul;15(3):796-806. doi: 10.1007/s13311-018-0610-y.

9.

Cannabinoid CB1 and CB2 Receptors, and Monoacylglycerol Lipase Gene Expression Alterations in the Basal Ganglia of Patients with Parkinson's Disease.

Navarrete F, García-Gutiérrez MS, Aracil-Fernández A, Lanciego JL, Manzanares J.

Neurotherapeutics. 2018 Apr;15(2):459-469. doi: 10.1007/s13311-018-0603-x.

10.

Usefulness of identifying G-protein-coupled receptor dimers for diagnosis and therapy of neurodegenerative diseases and of gliomas.

Reyes-Resina I, Aguinaga D, Labandeira-García JL, Lanciego JL, Navarro G, Franco R.

Histol Histopathol. 2018 Sep;33(9):909-917. doi: 10.14670/HH-11-963. Epub 2018 Jan 16. Review.

PMID:
29336473
11.

Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors.

Martínez-Pinilla E, Varani K, Reyes-Resina I, Angelats E, Vincenzi F, Ferreiro-Vera C, Oyarzabal J, Canela EI, Lanciego JL, Nadal X, Navarro G, Borea PA, Franco R.

Front Pharmacol. 2017 Oct 23;8:744. doi: 10.3389/fphar.2017.00744. eCollection 2017.

12.

Paracrine and Intracrine Angiotensin 1-7/Mas Receptor Axis in the Substantia Nigra of Rodents, Monkeys, and Humans.

Costa-Besada MA, Valenzuela R, Garrido-Gil P, Villar-Cheda B, Parga JA, Lanciego JL, Labandeira-Garcia JL.

Mol Neurobiol. 2018 Jul;55(7):5847-5867. doi: 10.1007/s12035-017-0805-y. Epub 2017 Oct 30.

PMID:
29086247
13.

AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy.

Morabito G, Giannelli SG, Ordazzo G, Bido S, Castoldi V, Indrigo M, Cabassi T, Cattaneo S, Luoni M, Cancellieri C, Sessa A, Bacigaluppi M, Taverna S, Leocani L, Lanciego JL, Broccoli V.

Mol Ther. 2017 Dec 6;25(12):2727-2742. doi: 10.1016/j.ymthe.2017.08.004. Epub 2017 Aug 10.

14.

Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia.

Navarro G, Borroto-Escuela D, Angelats E, Etayo Í, Reyes-Resina I, Pulido-Salgado M, Rodríguez-Pérez AI, Canela EI, Saura J, Lanciego JL, Labandeira-García JL, Saura CA, Fuxe K, Franco R.

Brain Behav Immun. 2018 Jan;67:139-151. doi: 10.1016/j.bbi.2017.08.015. Epub 2017 Aug 24.

PMID:
28843453
15.

Glucocerebrosidase expression patterns in the non-human primate brain.

Dopeso-Reyes IG, Sucunza D, Rico AJ, Pignataro D, Marín-Ramos D, Roda E, Rodríguez-Pérez AI, Labandeira-García JL, Lanciego JL.

Brain Struct Funct. 2018 Jan;223(1):343-355. doi: 10.1007/s00429-017-1504-1. Epub 2017 Aug 23.

16.

Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration.

Labandeira-Garcia JL, Rodríguez-Perez AI, Garrido-Gil P, Rodriguez-Pallares J, Lanciego JL, Guerra MJ.

Front Aging Neurosci. 2017 May 3;9:129. doi: 10.3389/fnagi.2017.00129. eCollection 2017. Review.

17.

Adeno-Associated Viral Vectors Serotype 8 for Cell-Specific Delivery of Therapeutic Genes in the Central Nervous System.

Pignataro D, Sucunza D, Vanrell L, Lopez-Franco E, Dopeso-Reyes IG, Vales A, Hommel M, Rico AJ, Lanciego JL, Gonzalez-Aseguinolaza G.

Front Neuroanat. 2017 Feb 10;11:2. doi: 10.3389/fnana.2017.00002. eCollection 2017.

18.

Expression of angiotensinogen and receptors for angiotensin and prorenin in the rat and monkey striatal neurons and glial cells.

Garrido-Gil P, Rodriguez-Perez AI, Fernandez-Rodriguez P, Lanciego JL, Labandeira-Garcia JL.

Brain Struct Funct. 2017 Aug;222(6):2559-2571. doi: 10.1007/s00429-016-1357-z. Epub 2017 Feb 4.

PMID:
28161727
19.

Gene therapy approaches in the non-human primate model of Parkinson's disease.

Pignataro D, Sucunza D, Rico AJ, Dopeso-Reyes IG, Roda E, Rodríguez-Perez AI, Labandeira-Garcia JL, Broccoli V, Kato S, Kobayashi K, Lanciego JL.

J Neural Transm (Vienna). 2018 Mar;125(3):575-589. doi: 10.1007/s00702-017-1681-3. Epub 2017 Jan 27. Review.

PMID:
28130586
20.

Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration.

Valenzuela R, Costa-Besada MA, Iglesias-Gonzalez J, Perez-Costas E, Villar-Cheda B, Garrido-Gil P, Melendez-Ferro M, Soto-Otero R, Lanciego JL, Henrion D, Franco R, Labandeira-Garcia JL.

Cell Death Dis. 2016 Oct 20;7(10):e2427. doi: 10.1038/cddis.2016.327.

21.

Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys.

Garbayo E, Ansorena E, Lana H, Carmona-Abellan MD, Marcilla I, Lanciego JL, Luquin MR, Blanco-Prieto MJ.

Biomaterials. 2016 Dec;110:11-23. doi: 10.1016/j.biomaterials.2016.09.015. Epub 2016 Sep 21.

PMID:
27697668
22.

Neurochemical evidence supporting dopamine D1-D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulation.

Rico AJ, Dopeso-Reyes IG, Martínez-Pinilla E, Sucunza D, Pignataro D, Roda E, Marín-Ramos D, Labandeira-García JL, George SR, Franco R, Lanciego JL.

Brain Struct Funct. 2017 May;222(4):1767-1784. doi: 10.1007/s00429-016-1306-x. Epub 2016 Sep 9.

23.

Disruption of a dopamine receptor complex amplifies the actions of cocaine.

Perreault ML, Hasbi A, Shen MYF, Fan T, Navarro G, Fletcher PJ, Franco R, Lanciego JL, George SR.

Eur Neuropsychopharmacol. 2016 Sep;26(9):1366-1377. doi: 10.1016/j.euroneuro.2016.07.008. Epub 2016 Jul 30.

PMID:
27480020
24.

Two Affinity Sites of the Cannabinoid Subtype 2 Receptor Identified by a Novel Homogeneous Binding Assay.

Martínez-Pinilla E, Rabal O, Reyes-Resina I, Zamarbide M, Navarro G, Sánchez-Arias JA, de Miguel I, Lanciego JL, Oyarzabal J, Franco R.

J Pharmacol Exp Ther. 2016 Sep;358(3):580-7. doi: 10.1124/jpet.116.234948. Epub 2016 Jun 29.

PMID:
27358483
25.

Basic Pharmacological and Structural Evidence for Class A G-Protein-Coupled Receptor Heteromerization.

Franco R, Martínez-Pinilla E, Lanciego JL, Navarro G.

Front Pharmacol. 2016 Mar 31;7:76. doi: 10.3389/fphar.2016.00076. eCollection 2016. Review.

26.

Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels.

Gómez-Vallejo V, Ugarte A, García-Barroso C, Cuadrado-Tejedor M, Szczupak B, Dopeso-Reyes IG, Lanciego JL, García-Osta A, Llop J, Oyarzabal J, Franco R.

J Neurochem. 2016 Jan;136(2):403-15. doi: 10.1111/jnc.13454.

27.

Hints on the Lateralization of Dopamine Binding to D1 Receptors in Rat Striatum.

Franco R, Casadó-Anguera V, Muñoz A, Petrovic M, Navarro G, Moreno E, Lanciego JL, Labandeira-García JL, Cortés A, Casadó V.

Mol Neurobiol. 2016 Oct;53(8):5436-45. doi: 10.1007/s12035-015-9468-8. Epub 2015 Oct 9.

PMID:
26452359
28.

Editorial: Parkinson's disease: cell vulnerability and disease progression.

Blesa J, Lanciego JL, Obeso JA.

Front Neuroanat. 2015 Sep 15;9:125. doi: 10.3389/fnana.2015.00125. eCollection 2015. No abstract available.

29.

Increased vulnerability to ethanol consumption in adolescent maternal separated mice.

García-Gutiérrez MS, Navarrete F, Aracil A, Bartoll A, Martínez-Gras I, Lanciego JL, Rubio G, Manzanares J.

Addict Biol. 2016 Jul;21(4):847-58. doi: 10.1111/adb.12266. Epub 2015 May 18.

PMID:
25988842
30.

Dopamine D2 and angiotensin II type 1 receptors form functional heteromers in rat striatum.

Martínez-Pinilla E, Rodríguez-Pérez AI, Navarro G, Aguinaga D, Moreno E, Lanciego JL, Labandeira-García JL, Franco R.

Biochem Pharmacol. 2015 Jul 15;96(2):131-42. doi: 10.1016/j.bcp.2015.05.006. Epub 2015 May 16.

PMID:
25986885
31.

Synaptic connectivity of the cholinergic axons in the olfactory bulb of the cynomolgus monkey.

Liberia T, Blasco-Ibáñez JM, Nácher J, Varea E, Lanciego JL, Crespo C.

Front Neuroanat. 2015 Mar 17;9:28. doi: 10.3389/fnana.2015.00028. eCollection 2015.

32.

Midbrain catecholaminergic neurons co-express α-synuclein and tau in progressive supranuclear palsy.

Erro Aguirre ME, Zelaya MV, Sánchez Ruiz de Gordoa J, Tuñón MT, Lanciego JL.

Front Neuroanat. 2015 Mar 11;9:25. doi: 10.3389/fnana.2015.00025. eCollection 2015.

33.

Calbindin content and differential vulnerability of midbrain efferent dopaminergic neurons in macaques.

Dopeso-Reyes IG, Rico AJ, Roda E, Sierra S, Pignataro D, Lanz M, Sucunza D, Chang-Azancot L, Lanciego JL.

Front Neuroanat. 2014 Dec 3;8:146. doi: 10.3389/fnana.2014.00146. eCollection 2014.

34.

Critical period for dopaminergic neuroprotection by hormonal replacement in menopausal rats.

Rodriguez-Perez AI, Borrajo A, Valenzuela R, Lanciego JL, Labandeira-Garcia JL.

Neurobiol Aging. 2015 Feb;36(2):1194-208. doi: 10.1016/j.neurobiolaging.2014.10.028. Epub 2014 Nov 1.

PMID:
25432430
35.

Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.

Farré D, Muñoz A, Moreno E, Reyes-Resina I, Canet-Pons J, Dopeso-Reyes IG, Rico AJ, Lluís C, Mallol J, Navarro G, Canela EI, Cortés A, Labandeira-García JL, Casadó V, Lanciego JL, Franco R.

Mol Neurobiol. 2015 Dec;52(3):1408-1420. doi: 10.1007/s12035-014-8936-x. Epub 2014 Oct 26.

PMID:
25344317
36.

Striatal vessels receive phosphorylated tyrosine hydroxylase-rich innervation from midbrain dopaminergic neurons.

Afonso-Oramas D, Cruz-Muros I, Castro-Hernández J, Salas-Hernández J, Barroso-Chinea P, García-Hernández S, Lanciego JL, González-Hernández T.

Front Neuroanat. 2014 Aug 26;8:84. doi: 10.3389/fnana.2014.00084. eCollection 2014.

37.

Phosphodiesterase inhibition in cognitive decline.

García-Barroso C, Ugarte A, Martínez M, Rico AJ, Lanciego JL, Franco R, Oyarzabal J, Cuadrado-Tejedor M, García-Osta A.

J Alzheimers Dis. 2014;42 Suppl 4:S561-73. doi: 10.3233/JAD-141341. Review.

PMID:
25125473
38.

Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism.

Sierra S, Luquin N, Rico AJ, Gómez-Bautista V, Roda E, Dopeso-Reyes IG, Vázquez A, Martínez-Pinilla E, Labandeira-García JL, Franco R, Lanciego JL.

Brain Struct Funct. 2015 Sep;220(5):2721-38. doi: 10.1007/s00429-014-0823-8. Epub 2014 Jun 28.

39.

CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum.

Martínez-Pinilla E, Reyes-Resina I, Oñatibia-Astibia A, Zamarbide M, Ricobaraza A, Navarro G, Moreno E, Dopeso-Reyes IG, Sierra S, Rico AJ, Roda E, Lanciego JL, Franco R.

Exp Neurol. 2014 Nov;261:44-52. doi: 10.1016/j.expneurol.2014.06.017. Epub 2014 Jun 23.

PMID:
24967683
40.

G-protein-coupled receptor heteromers as key players in the molecular architecture of the central nervous system.

Brugarolas M, Navarro G, Martínez-Pinilla E, Angelats E, Casadó V, Lanciego JL, Franco R.

CNS Neurosci Ther. 2014 Aug;20(8):703-9. doi: 10.1111/cns.12277. Epub 2014 May 9. Review.

41.

Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease.

Cerri S, Levandis G, Ambrosi G, Montepeloso E, Antoninetti GF, Franco R, Lanciego JL, Baqi Y, Müller CE, Pinna A, Blandini F, Armentero MT.

J Neuropathol Exp Neurol. 2014 May;73(5):414-24. doi: 10.1097/NEN.0000000000000064.

PMID:
24709676
42.

L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.

Pinna A, Bonaventura J, Farré D, Sánchez M, Simola N, Mallol J, Lluís C, Costa G, Baqi Y, Müller CE, Cortés A, McCormick P, Canela EI, Martínez-Pinilla E, Lanciego JL, Casadó V, Armentero MT, Franco R.

Exp Neurol. 2014 Mar;253:180-91. doi: 10.1016/j.expneurol.2013.12.021. Epub 2014 Jan 9.

PMID:
24412491
43.

L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus.

Bonaventura J, Rico AJ, Moreno E, Sierra S, Sánchez M, Luquin N, Farré D, Müller CE, Martínez-Pinilla E, Cortés A, Mallol J, Armentero MT, Pinna A, Canela EI, Lluís C, McCormick PJ, Lanciego JL, Casadó V, Franco R.

Neuropharmacology. 2014 Apr;79:90-100. doi: 10.1016/j.neuropharm.2013.10.036. Epub 2013 Nov 11.

PMID:
24230991
44.

Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease.

Rodriguez-Perez AI, Dominguez-Meijide A, Lanciego JL, Guerra MJ, Labandeira-Garcia JL.

Neurobiol Dis. 2013 Oct;58:209-19. doi: 10.1016/j.nbd.2013.06.004. Epub 2013 Jun 14.

PMID:
23774254
45.

Functional neuroanatomy of the basal ganglia.

Lanciego JL, Luquin N, Obeso JA.

Cold Spring Harb Perspect Med. 2012 Dec 1;2(12):a009621. doi: 10.1101/cshperspect.a009621.

46.

Loss of parvalbumin-positive neurons from the globus pallidus in animal models of Parkinson disease.

Fernández-Suárez D, Celorrio M, Lanciego JL, Franco R, Aymerich MS.

J Neuropathol Exp Neurol. 2012 Nov;71(11):973-82. doi: 10.1097/NEN.0b013e3182717cba.

PMID:
23044920
47.

Dopaminergic degeneration is enhanced by chronic brain hypoperfusion and inhibited by angiotensin receptor blockage.

Rodriguez-Perez AI, Dominguez-Meijide A, Lanciego JL, Guerra MJ, Labandeira-Garcia JL.

Age (Dordr). 2013 Oct;35(5):1675-90. doi: 10.1007/s11357-012-9470-2. Epub 2012 Sep 18.

48.

Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD.

García-Barroso C, Ricobaraza A, Pascual-Lucas M, Unceta N, Rico AJ, Goicolea MA, Sallés J, Lanciego JL, Oyarzabal J, Franco R, Cuadrado-Tejedor M, García-Osta A.

Neuropharmacology. 2013 Jan;64:114-23. doi: 10.1016/j.neuropharm.2012.06.052. Epub 2012 Jul 7.

PMID:
22776546
49.

Two types of periglomerular cells in the olfactory bulb of the macaque monkey (Macaca fascicularis).

Liberia T, Blasco-Ibáñez JM, Nácher J, Varea E, Lanciego JL, Crespo C.

Brain Struct Funct. 2013 Jul;218(4):873-87. doi: 10.1007/s00429-012-0435-0. Epub 2012 Jun 12.

PMID:
22684581
50.

Unmasking adenosine 2A receptors (A2ARs) in monkey basal ganglia output neurons using cholera toxin subunit B (CTB).

Luquin N, Sierra S, Rico AJ, Gómez-Bautista V, Roda E, Conte-Perales L, Franco R, McCormick P, Labandeira-García JL, Lanciego JL.

Neurobiol Dis. 2012 Sep;47(3):347-57. doi: 10.1016/j.nbd.2012.05.006. Epub 2012 May 31.

PMID:
22659306

Supplemental Content

Loading ...
Support Center